CERo 10-Q: Going Concern Doubt, $650K Cash, Pending Subsidiary Sale to SRX
CERO sits 55% above its 52-week low of $0.003.
Summary
CERo reported $650,681 of cash and reiterated substantial doubt about its ability to continue as a going concern, with its survival now hinging on the pending sale of its operating subsidiary to SRX after the go-shop period closed with no rival bids.
Key Events · Earnings and Guidance · CERO
-
Going Concern Doubt Reiterated
As of September 30, 2026 the company held $650,681 of cash, restricted cash and equivalents against a working capital deficit of about $19.3 million, and said cash will not fund operations for one year.
-
Subsidiary Sale to SRX Pending
Under the October 6, 2026 Stock Purchase Agreement, CERo would sell all stock of CERo Therapeutics, Inc. to SRX for $1,000,000 of SRX common stock, discharge of the Consolidated Note (up to $11,666,109 principal) and buyer assumption of about $1.5 million of liabilities; the go-shop expired November 5, 2026 with no superior proposals.
-
Q3 Profit Is Non-Cash
Q3 2026 net income of $4,019,112 came from a $3,801,413 gain on debt extinguishment and a $3,724,886 gain on preferred stock liability remeasurement; nine-month net loss was $2,895,632.
-
Massive Preferred Dilution
Conversion prices on Series D and E preferred were cut from $0.05 to $0.01, producing $28,426,624 of deemed dividends in nine months; diluted weighted shares for Q3 were 1,090,811,877 versus 72,844,427 basic.
Analysis · CERO · Life Sciences
CERo ended Q3 2026 with just $650,681 of cash and a $19.3 million working capital deficit, and management states plainly that cash will not fund operations for one year — substantial doubt about going concern. The only visible path forward is the October 6, 2026 Stock Purchase Agreement to sell the entire operating subsidiary to SRX Global, which would cancel up to $11.67 million of secured debt and hand the company $1 million of SRX stock plus assumption of about $1.5 million of liabilities. That deal's go-shop window closed November 5, 2026 with no competing bids, so the company is now dependent on a single counterparty closing. Meanwhile the capital structure is severely impaired: preferred conversion prices were cut from $0.05 to $0.01, generating $28.4 million of deemed dividends in nine months, and the diluted share count used in the Q3 EPS calculation was 1.09 billion versus 72.8 million basic. The reported $4.0 million Q3 net income is an accounting artifact of non-cash gains on preferred stock remeasurement and debt extinguishment, not operating performance.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CERO was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $382.6K. The 52-week trading range was $0.00 to $0.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.